Skip to main content

Table 2 Survival of patients with various histologic subtypes

From: Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Histology

n

%

PFS [months, (95% CI)]

OS [months, (95% CI)]

Leiomyosarcoma

9

20.9

5.6 (2.7-8.5)

9.9 (5.3-14.4)

Angiosarcoma

6

14.0

3.2 (2.1-4.2)

8.0 (3.7-12.4)

MFH/UPS

5

11.6

7.1 (0.3-13.8)

7.5 (1.1-13.9)

MPNST

5

11.6

6.5 (0.7-12.3)

8.9 (3.5-14.3)

Fibroblastic tumor

4

9.3

5.7 (0.7-10.8)

6.4 (1.6-11.2)

Synovial sarcoma

4

9.3

7.7 (3.5-11.9)

9.4 (4.4-14.5)

Rhabdomyosarcoma

3

7.0

0.9 (0.5-1.3)

2.5 (0.7-4.4)

Liposarcoma

2

4.7

1.3 (0.7-1.9)

1.5 (1.1-1.8)

Tumor of uncertain differentiation

3

7.0

1.4 (0.5-2.3)

4.1 (−0.4-8.5)

Desmoplastic small cell tumor

1

2.3

10.3 (N/A)

43.4 (N/A)

PEComa

1

2.3

3.8 (N/A)

4.1 (N/A)

Total

43

100

5.0 (3.6-6.4)

8.2 (5.8-10.6)

  1. PFS = progression-free survival, CI = confidence interval, OS = overall survival, MFH/UPS = malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma, MPNST = malignant peripheral nerve sheath tumor, PEComa = perivascular epithelioid cell tumor; N/A, not available.